User contributions
Jump to navigation
Jump to search
- 15:37, 19 June 2009 diff hist 3,712 bytes FDG-PET Biomarker Ctte
- 15:37, 19 June 2009 diff hist 3,714 bytes FDG-PET Biomarker Ctte
- 20:20, 31 March 2009 diff hist 1,325 bytes Main Page
- 20:18, 31 March 2009 diff hist 178 bytes File:Profiling.ppt This files was first used in the FDG-PET meeting on 3/31/09, as a way of representing what the vCT group has been developing. It will also be shared with the DCE-MRI group soon. current
- 17:59, 23 March 2009 diff hist 1,264 bytes Main Page
- 17:56, 23 March 2009 diff hist 126 bytes File:Oncology section.ppt This is a raw result from the Oncology section of the Imaging Biomarkers Roundtabl;e meeting held in Chicago 16-17 March 2009. current
- 22:14, 19 March 2009 diff hist 3,194 bytes CT Volumetry Biomarker Ctte
- 17:22, 3 March 2009 diff hist 3,142 bytes CT Volumetry Biomarker Ctte
- 17:17, 3 March 2009 diff hist empty File:We Can Do Better.jpg current
- 17:16, 3 March 2009 diff hist empty File:RECIST Baseline.jpg uploaded a new version of "Image:RECIST Baseline.jpg" current
- 17:07, 3 March 2009 diff hist empty File:Therapy Assessment.jpg current
- 16:52, 3 March 2009 diff hist empty File:RECIST Baseline.ppt current
- 16:50, 3 March 2009 diff hist empty File:RECIST Baseline.gif uploaded a new version of "Image:RECIST Baseline.gif" current
- 16:49, 3 March 2009 diff hist empty File:RECIST Baseline.gif uploaded a new version of "Image:RECIST Baseline.gif"
- 16:46, 3 March 2009 diff hist empty File:RECIST Baseline.gif
- 16:34, 3 March 2009 diff hist empty File:RECIST Baseline.jpg uploaded a new version of "Image:RECIST Baseline.jpg"
- 16:22, 3 March 2009 diff hist empty File:RECIST Baseline.jpg uploaded a new version of "Image:RECIST Baseline.jpg"
- 16:13, 3 March 2009 diff hist empty File:RECIST Baseline.jpg
- 13:04, 22 January 2009 diff hist 2,587 bytes CT Volumetry Biomarker Ctte
- 13:04, 22 January 2009 diff hist 65 bytes CT Lung Nodule Volume Quantification Profile CT Lung Nodule Volume Quantification Profile moved to Primary/Regional Nodes and Metastatic Sites Profile: Our team has commissioned a sub-committee to determine how best to make the profiles clinically relevant, and this is what they have chosen current